Do you want to read an article? Please log in or register.
KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in cisplatin-ineligible patients with muscle-invasive bladder cancer
Genitourinary Cancer
ESMO 2026
Related content
ESMO 2026
Genitourinary Cancer
LBA2: VOLGA: Perioperative durvalumab plus enfortumab vedotin significantly improves EFS and OS in patients with MIBC
Genitourinary Cancer
Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Int J Cancer
Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM
doi: 10.1002/ijc.70525
Genitourinary Cancer
Promising Perioperative Regimen for Cisplatin-Eligible MIBC
ESMO 2026
Genitourinary Cancer
NIAGARA: Perioperative durvalumab demonstrates broad EFS benefit across molecular subtypes of muscle-invasive bladder cancer
Genitourinary Cancer
Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged ≤45: A Retrospective Matched Cohort Study
J Urol
St-Laurent MP, Din S, Moryousef J, Lajkosz K, Kwong JCC, Chan A, Kim J, Taborek A, Chadee A, Sadri I, Reznik G, Tin C, Fleshner NE, Kulkarni GS, Black PC, Kassouf W, Zlotta AR
doi: 10.1097/JU.0000000000005183
SPECIAL REPORT
Gynecologic Cancer
Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer
Genitourinary Cancer
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
Eur Urol
Gupta S, Li R, Hensley PJ, Daneshmand S, Faltas BM, Grivas P, Lobo N, Mir MC, Meeks JJ, Mouw KW, Moschini M, Necchi A, Oualla K, Pohar KS, Rosenberg JE, Schmidt B, Siefker-Radtke AO, Steinberg GD, Stenzl A, Buckley RJ, Kamat AM
doi: 10.1016/j.eururo.2026.01.029
COMMENTED
Lung, Respiratory and Thoracic Cancer
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Ann Oncol
Wakelee H, Spicer JD, Gao S, Liberman M, Tsuboi M, Kato T, Chen KN, Dooms C, Majem M, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Halmos B, Jones DR, Chaft JE, Reck M, Jensen E, Keller SM, Samkari A, Garassino MC
doi: 10.1016/j.annonc.2026.08.005
Genitourinary Cancer
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer
BJU Int
McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA
doi: 10.1111/bju.70044